05 Dec Tocilizumab High Active For Refractory Graft vs Host Disease
MedicalResearch.com Interview with:
Alex Ganetsky, PharmD, BCOP
Clinical Pharmacy Specialist – Hematology/BMT
Hospital of the University of Pennsylvania
MedicalResearch.com: What is the background for this study? What are the main findings?
• Allogeneic hematopoietic cell transplant (HCT) recipients with steroid-refractory gastrointestinal acute graft-versus-host disease (GI-GVHD) have poor outcomes.
• There is no consensus for optimal treatment of these patients.
• We retrospectively evaluated the efficacy of tocilizumab, an interleukin-6 receptor monoclonal antibody, for the treatment of steroid-refractory GI-GVHD.
• 10/11 (91%) patients achieved a complete response after a median time of 11 days (range, 2 – 18) from tocilizumab initiation.
• The median time to response onset, defined as improvement in GVHD stage by at least 1, was 1 day (range, 1 – 6).
• At a median follow-up of 3 months (range, 1.1 – 12.8) from tocilizumab initiation, 8 of 11 patients are alive and free of the their underlying hematologic malignancy.
• No associations between serum levels of IL-6 and tocilizumab response could be identified.
MedicalResearch.com: What should readers take away from your report?
• Tocilizumab appears to be highly active for the treatment of steroid-refractory GI-GVHD.
• Of note, this a retrospective analysis involving a small number of patients and thus detailed evaluation through prospective clinical trials is warranted.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
• Our findings provide the rationale for studying tocilizumab in the treatment of steroid-refractory GI-GVHD in a prospective trial to better understand tocilizumab’s efficacy and safety profile in the HCT setting.
• It is also critical to further characterize the precise mechanism associated with tocilizumab’s activity in GVHD particularly involving the GI tract.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
upcoming ASH abstract:
Tocilizumab Is Highly Active for Severe Steroid-Refractory Acute Graft-Versus-Host Disease of the Gastrointestinal Tract
Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution
Program: Oral and Poster Abstracts
Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I
Saturday, December 3, 2016, 5:30 PM-7:30 PM
Hall GH (San Diego Convention Center)
Alex Ganetsky, PharmD, BCOP1,2*, Noelle V Frey, MD2, Alison W Loren, MD, MS3, Elizabeth O. Hexner, MD4, James K Mangan, MD, PhD2, Saar I Gill, MBBS, PhD2,5, Selina Luger, MD2, Adam D. Cohen, MD6, Daria V. Babushok, MD, PhD7, Edward A Stadtmauer, MD7, Jacqueline Smith, CRNP7*, William R. Drobyski, MD8, Sarah K Kraus, PharmD1*, Colleen Timlin, PharmD, BCOP1,7* and David L. Porter, MD7
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.
More Medical Research Interviews on MedicalResearch.com
Last Updated on December 5, 2016 by Marie Benz MD FAAD